Летонија - Летонски - Zāļu valsts aģentūra

baxalta innovations gmbh, austria - albumīns, cilvēka - Šķīdums infūzijām - 200 g/l

Европска Унија - Летонски - EMA (European Medicines Agency)

hansa biopharma ab - imlifidase - desensitization, immunologic; kidney transplantation - imūnsupresanti - idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. the use of idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

Европска Унија - Летонски - EMA (European Medicines Agency)

novartis europharm limited - crizanlizumab - anēmija, sirpjveida šūna - other hematological agents - adakveo is indicated for the prevention of recurrent vaso occlusive crises (vocs) in sickle cell disease patients aged 16 years and older. it can be given as an add on therapy to hydroxyurea/hydroxycarbamide (hu/hc) or as monotherapy in patients for whom hu/hc is inappropriate or inadequate.

Европска Унија - Летонски - EMA (European Medicines Agency)

boehringer ingelheim international gmbh - spesolimab - psoriāze - imūnsupresanti - spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (gpp) as monotherapy.

Европска Унија - Летонски - EMA (European Medicines Agency)

swedish orphan biovitrum ab - loncastuximab tesirine - lymphoma, large b-cell, diffuse; lymphoma, b-cell - antineoplastiski līdzekļi - zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl), after two or more lines of systemic therapy.

Европска Унија - Летонски - EMA (European Medicines Agency)

novartis europharm limited - tislelizumab - esophageal squamous cell carcinoma - antineoplastiski līdzekļi - oesophageal squamous cell carcinoma (oscc) tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy.

Летонија - Летонски - Zāļu valsts aģentūra

baltijas terapeitiskais serviss, sia, latvia - albumīns, cilvēka - Šķīdums infūzijām - 20%

Летонија - Летонски - Zāļu valsts aģentūra

baxalta innovations gmbh, austria - albumīns, cilvēka - Šķīdums infūzijām - 200 g/l

Летонија - Летонски - Zāļu valsts aģentūra

baxalta innovations gmbh, austria - albumīns, cilvēka - Šķīdums infūzijām - 50 g/l

Европска Унија - Летонски - EMA (European Medicines Agency)

takeda manufacturing austria ag - cilvēka olbaltumviela c. - purpura fulminans; protein c deficiency - antitrombotiskie līdzekļi - ceprotin is indicated for prophylaxis and treatment of  purpura fulminans  coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein c deficiency.